HCPCS Level II code Q5118 describes injection of bevacizumab-bvzr (Zirabev) supplied as a 10 mg unit; this code represents administration of the bevacizumab biosimilar product and is used for billing the drug component when provided in outpatient settings such as infusion centers, oncology clinics, or hospital outpatient departments for systemic anti-VEGF therapy.

For related coverage guidance, see recent payer policy updates: B-Hemolytic Streptococcus Testing, Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance Assays, Hepatitis Testing (A, B, C, D) Coverage Criteria.